Tonix Pharmaceuticals has signed a research collaboration and exclusive licensing agreement with the University of Alberta in Canada for three new vaccine candidates to prevent Covid-19.
The partnership will develop the three vaccine candidates, which are based on the horsepox vector platform and designed to express various SARS-CoV-2 antigens.
In February this year, Tonix Pharmaceuticals collaborated with non-profit Southern Research to develop another Covid-19 vaccine candidate, TNX-1800, which is also based on horsepox vector platform but designed to express SARS-CoV-2 Spike protein.
The three newly licensed Covid-19 vaccine candidates are named TNX-1810, TNX-1820 and TNX-1830. Horsepox is the vector system that forms the company’s